Cepheid Product Pipeline Analysis, Q4, 2019 Update - Partnership with Small & Large Biopharmaceutical Companies to Develop Therapies in Anti-Infective, Critical Infectious Disease & Oncology Areas - ResearchAndMarkets.com
Cepheid, a subsidiary of Danaher Corporation, is a molecular diagnostic company that develops, manufactures and markets molecular systems and tests for clinical and non-clinical markets. The company offers in vitro diagnostic tests for health care associated infections, critical infectious diseases, sexual health, and oncology and genetics; molecular diagnostic systems; and reagents and parts. Cepheid distributes its products directly and through a network of distributors across Americas, Asia, Europe, Africa and the Middle East regions. The company has partnership with small and large biopharmaceutical companies to develop therapies in anti-infective, critical infectious disease and oncology areas. Cepheid is headquartered in Sunnyvale, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Cepheid
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Key Topics Covered:
Cepheid Company Overview
Cepheid Company Snapshot
Cepheid Pipeline Products and Ongoing Clinical Trials Overview
Cepheid - Pipeline Analysis Overview
Business Description
Cepheid - Key Facts
Cepheid - Major Products and Services
Cepheid Pipeline Products by Development Stage
Cepheid Ongoing Clinical Trials by Trial Status
Cepheid Pipeline Products Overview
GeneXpert - Xpert HPV CLIA Waived
GeneXpert Omni Clinical Trial
GeneXpert Omni - Flu/RSV CW
GeneXpert Omni - HIV-1 Qualitative Test
GeneXpert Omni - MTB/RIF
GeneXpert Omni - Xpert HPV
GeneXpert Omni - Xpert MTB/RIF Ultra
GeneXpert Omni - Xpress Flu CW
GeneXpert Omni - Xpress GAS CW
GeneXpert Omni - Xpress Pertussis CW
GeneXpert Omni - Xpress Vaginitis/Vaginosis CW
POC Catridge - Viral Hemorrhagic Fever
Urine Based Screening Test - Cervical Cancer
Xpert BCR-ABL Ultra - Acute Lymphocytic Leukemia
Xpert BCR-ABL Ultra - Solid Tumors
Xpert Bladder Cancer Asymptomatic Assay
Xpert Bladder Cancer Monitor Test Clinical Trial
Xpert Bladder Cancer Symptomatic Assay
Xpert Breast CA Prognostic Signature Assay
Xpert Breast CA Stratifier Assay
XPERT CLL Monitoring Test
Xpert CMV Viral Load Assay
Xpert CT/NG FluroQ Resistant Trichomonas Assay
Xpert CT/NG LBC Assay
Xpert EBV / NPC Screen
Xpert EGFR Monitor (Lung) Test
Xpert GBS Ultra
Xpert Group A Strep Assay
Xpert HCV Quant Assay
Xpert HSV 1 And 2 Test
Xpert Lung CA Early Detection Test
Xpert Microbial ID Assay
Xpert MTB/RIF Ultra
Xpert MTB/XDR Test
Xpert Next Generation MRSA/SA SSTI Assay
Xpert Next Generation SA Nasal Complete Assay
XPERT Pancreatic CA Early Detection Test
Xpert Pertussis Assay
Xpert Prostate CA Early Detection Test
Xpert Respiratory Panel Assay
Xpert Sepsis Fungal Assay
Xpert Vaginitis Assay
Xpert VZV Assay
Cepheid - Key Competitors
Cepheid - Key Employees
Cepheid - Key Employee Biographies
Cepheid - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Cepheid, Recent Developments
Oct 02, 2019: Cepheid Receives FDA Clearance for Xpert BCR-ABL Ultra Test
Jun 10, 2019: Xpert Ultra test for diagnosing TB now included in Cochrane Review
May 29, 2019: Cepheid receives FDA clearance for extragenital claims for Xpert CT/NG test
May 24, 2019: FDA clears diagnostic tests for chlamydia and gonorrhoea
Apr 27, 2019: SpeeDx and Cepheid announce test partnership
Dec 20, 2018: Cepheid receives CE-IVD clearance for Xpert HBV Viral Load
Sep 24, 2018: Johnson & Johnson announces 10-year initiative to help end tuberculosis, the World's 1 Infectious Killer
Rubrik, Inc. today announced the pricing of its upsized initial public offering of 23,500,000 shares of its Class A common stock at a public offering price of $32.00 per share. In addition, Rubrik has granted the underwriters a 30-day option to...
Labcorp , a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company. Before the transaction can proceed,...
Invitae , a leading medical genetics company, announced that Labcorp , a global leader of innovative and comprehensive laboratory services, has been selected...
The Board of Directors of TransAlta Corporation declared a quarterly dividend of $0.06 per common share payable on July 1, 2024 to shareholders of record at the close of business on June 1, 2024. The Board of Directors also declared the following...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from four clinical studies of the company's three key...